CONGRESS AMBASSADORS

Register your Interest

A BIG THANK YOU TO OUR CONGRESS AMBASSADORS

The World Healthcare Congress Europe Ambassador programme recognises people who have worked with us to amplify the importance of the topics being discussed at WHCE 2019. The ambassadors are experts within their field who are supporting health and social care innovation to drive change to ultimately ensure the future sustainability of healthcare systems.

Are you interested in being a WHCE Ambassador? Contact us at whce2019@conferencepartners.com for more information.

  • Steve Tremitiere
    Steve Tremitiere
  • Colleen M. Kigin
    Colleen M. Kigin
  • Prof Nikolaos Strimpakos
    Prof Nikolaos Strimpakos
  • Prof Christopher Levi
    Prof Christopher Levi
  • Prof Mark Lawler
    Prof Mark Lawler

SUPPORTERS

WORLD HEALTH CARE CONGRESS EUROPE European Union Trade Mark Reg. No. 16995789

Steve Tremitiere

Founder and CEO of GrayHare Ventures and Chief Development Officer for Briovation

Steve Tremitiere is Founder and CEO of GrayHare Ventures and the Chief Development Officer for Briovation.  Steve has 30 years of experience in strategic business development across a wide range of industries with focus on health and technology, and has an extensive background working with startups and new business initiatives.  He is currently engaged with a large national health system to launch a highly innovative population health initiative, and also leads Briovation’s development efforts as it looks to transform health care investing. In addition to his professional work he serves on advisory boards for a number of social impact organizations including Esther Dyson’s Wellville Initiative, EveryoneOn, Village Capital, Social Innovations Lab and the WISER Girls Initiative in Kenya.

Colleen M. Kigin

PT, DPT, FAPTA

Colleen M. Kigin, PT, DPT, FAPTA presently serves as a Clinical Professor and Chair of the Scholarship and Endowment Board for the University of Colorado Physical Therapy Program, University of Colorado School of Medicine, Denver, Colorado, USA. From 2014-2015, Dr. Kigin served as a consultant to the University of Manchester, Manchester Academic Health Science Centre, UK and for Strategic Analysis, assigned to the Defense Advance Research Projects Agency (DARPA) for the US military, focused on healthcare innovation. Prior to this, she served as Chief of Staff for the Center of Integration of Medicine and Innovative Technology, a 12 institution consortium developing innovative solutions to healthcare problems.

In 1994, she joined the newly formed Partners HealthCare System in Boston, Massachusetts, coordinating the system’s cost reduction efforts from 1994 to 1998. Dr. Kigin previously served as the Director of Physical Therapy Services at Massachusetts General Hospital, and Assistant Professor at the MGH Institute of Health Professions (MGH IHP) Dr. Kigin earned a Bachelor of Science in Physical Therapy at the University of Colorado, Master of Science at Boston University, Master in Public Administration from the Harvard Kennedy School of Government and Doctor in Physical Therapy from the MGH IHP.

Prof Nikolaos Strimpakos

Department of Physiotherapy, TEI of Sterea Ellada, Lamia, Greece

Dr. Nikolaos Strimpakos is a Professor of Physiotherapy, in Physiotherapy Department, TEI of Sterea Ellada and holds Honorary contracts as Research Associate from the University of Manchester and from the University of Athens. He has an MSc in Physiotherapy (2000) and a PhD in Rehabilitation Science (2004) from University of Manchester with specific interest in musculoskeletal assessment and rehabilitation. He has attended numerous post-graduate courses and seminars and he has published more than 40 peer reviewed papers in international journals having up to now more than 1400 citations while he has been principal investigator or member of the main research team in several research proposals the last years (https://www.researchgate.net/profile/Nikolaos_Strimpakos). Dr. Strimpakos is currently Vice-Rector of TEI of Sterea Ellada, Director of the Center of Technological Research of Central Greece and Head of MSc in Advanced Physiotherapy. He is also a member of Education Matters Working Group and Foundation Working Group of the World Confe

deration for Physical Therapy-European Region (WCPT-ER).

Prof Christopher Levi

Executive Director, Sydney Partnership for Health, Education, Research and Enterprise (SPHERE)
Professor of Medicine, University of NSW
Conjoint Professor of Medicine, University of Newcastle
Honorary Medical Officer, John Hunter Hospital, Newcastle
Fellow, Australian Academy of Health and Medical Sciences (FAHMS)

Recent Previous Positions:
Director, Clinical Research and Translation, Research Innovation and Partnership, Hunter New England Local Health District (2014-2017)
Senior Staff Specialist (Neurology), Hunter New England Local Health District (1998-2017)
Clinical Lead, Hunter New England Stroke Stream, HNE Local Health District (2012-2017)

Qualifications: B Med Sci, MBBS, FRACP.

Academic Leadership: Prof Levi established the Hunter Medical Research Institute/University of Newcastle Stroke Research Program in 1998. The success of this program led to its incorporation into the University of Newcastle Priority Research Centre for Translational Neuroscience and Mental Health Research (PRC) in 2007, and in 2016 the Priority Research Centre for Stroke and Brain Injury was established at the University. In 2008 he established the Australian Stroke Genetics Collaborative (ASGC) represents the ASGC on the International Stroke Genetics Consortium meta-analysis group, ‘Metastroke’.

Prof Levi led the successful 2016 bid for the NSW Regional Health Partners to gain status as one of Australia’s first National Health and Medical Research Council (NHMRC) Centres for Innovation in Regional Health. He compiled the bid on behalf of Hunter New England, Central Coast and Mid-North Coast Local Health Districts, Universities of Newcastle and New England, and the Hunter New England Central Coast Primary Health Network. In mid-2017, Prof Levi took up the role of Executive Director of the Sydney Partnership for Health, Education, Research and Enterprise (SPHERE), but maintains his research role with the University of Newcastle/Hunter Medical Research Institute.

TRACK RECORD:
Prof Levi’s direct leadership and research activity is focussed on the areas of clinical trials in acute stroke, stroke genetics, advanced acute imaging, and cluster randomised trials focussing on implementation of evidenced based stroke care. Prof Levi has a proven ability to conceive, conduct, manage and publish clinically relevant research in the highest ranking clinical journals (H-index: 48; career publications: 280; career citations: 10,130), with the majority of this output occurring in the last five years (publications in the last five years: 149; citations in the last five years: 7,143). He is a highly respected clinician researcher with >200 invited talks and sessions chaired at major national and international meetings. Prof Levi has a solid foundation of active NHMRC Program, Project and Partnership grants where the scope of research work and research management is substantial. He has well established research outputs and involvement in national research governance and leadership requirements. His strong international reputation is supported by publications in preeminent journals such as Nature Genetics, New England Journal of Medicine, and Lancet, and his election as a Fellow of the Australian Academy of Health and Medical Sciences.

Contribution to field of research: Prof Levi oversees a broad portfolio of stroke research within his group. The Tenecteplase versus Alteplase in Acute Ischaemic Stroke has been published in the New England Journal of Medicine and is the first randomised trial to show superiority of an alternative thrombolytic agent over the standard treatment option. This work has led to NHMRC funding (APP1079696) for the international multicentre phase III trial, TASTE. He led an NHMRC Partnership Grant (569328) funded cluster randomised trial across 20 Australian acute stroke units testing strategies to better implement thrombolysis for acute ischaemic stroke (TIPS). The benefits of the translational focus of Prof Levi’s research has been spectacularly demonstrated with the establishment of 22 stroke units across New South Wales under his inaugural chairmanship of the NSW Greater Metropolitan Clinical Taskforce for Stroke.

Collaborations: Prof Levi is co-principal investigator on the Tenecteplase versus Alteplase for Stroke Thrombolysis Evaluation (TASTE) trial, an international randomised trial which is being run across 50 academic stroke centres in Australia, Canada, Taiwan, the United Kingdom, Spain and Belgium. He led an NHMRC Partnership Grant funded cluster randomised trial across 20 Australian acute stroke units testing strategies to better implement thrombolysis for acute ischaemic stroke (TIPS). Prof Levi was CIA on a successful Australian Stroke Genetics Collaboration NHMRC project grant, which to date has led to two co-authored publications in Nature Genetics, and others in Lancet Neurology, Stroke, Neurology and Annals of Neurology. He was also instrumental in establishing an international collaboration between the University of Newcastle and Hunter Medical Research Institute, and Harbin Medical University and its major teaching hospitals, the First and Second Affiliated Hospitals in China. This program supports an active exchange of researchers. An example of cross-organisational research involved the establishment of the pre-hospital acute stroke protocol (PAST), a unique collaboration between the Acute Stroke Service and NSW Ambulance. This work established a regional ambulance protocol for rapid assessment and transfer, and led to a world-leading 21% of all ischaemic stroke patients being treated with tPA.

Professional and peer review involvement: Prof Levi supports NHMRC (Grant Review Panel membership 2013,14,15; Assigner Academy 2016), AAHMS (inducted in 2015, now media communications group member), ARC (ERA Research Evaluation Committee 2012) along with clinical professional groups (Stroke Society of Australasia Committee 2014-16; National Stroke Foundation Council 2010-16; Australasian Stroke Academy Founding Member and Senior Advisor). He serves on the Editorial Board of the Medical Journal of Australia and the International Journal of Stroke, and is a regular reviewer for the journals Stroke, Neurology, Cerebrovascular Diseases, Internal Medicine Journal and has undertaken reviews for Lancet and Lancet Neurology.

CURRENT RESEARCH SUPPORT:

 

TOP FIVE PUBLICATIONS:

  1. Anderson CS, Robinson T, Lindley RI, Arima H, Lavados PM, Lee TH, Broderick JP, Chen X, Chen G, Sharma VK, Kim JS, Thang NH, Cao Y, Parsons MW, Levi C, Huang Y, Olavarría VV, Demchuk AM, Bath PM, Donnan GA, Martins S, Pontes-Neto OM, Silva F, Ricci S, Roffe C, Pandian J, Billot L, Woodward M, Li Q, Wang X, Wang J, Chalmers J; ENCHANTED Investigators and Coordinators. Low-dose versus standard-dose intravenous alteplase in acute ischemic stroke. N Engl J Med. 2016;374:2313-23 (Citations: 55). Conceptualisation, design, funding and conduct as CI, Steering Committee member. Practice influencing trial showing low-dose alteplase was not inferior to standard-dose alteplase, particularly in patients on concomitant antiplatelet therapy with fewer symptomatic haemorrhages. Trial ushers in a new era of ‘tailored’ alteplase therapy.
  2. Campbell BC, Mitchell PJ, Kleinig TJ, Dewey HM, Churilov L, Yassi N, Yan B, Dowling RJ, Parsons MW, Oxley TJ, Wu TY, Brooks M, Simpson MA, Miteff F, Levi CR, Krause M, Harrington TJ, Faulder KC, Steinfort BS, Priglinger M, Ang T, Scroop R, Barber PA, McGuinness B, Wijeratne T, Phan TG, Chong W, Chandra RV, Bladin CF, Badve M, Rice H, de Villiers L, Ma H, Desmond PM, Donnan GA, Davis SM; EXTEND-IA Investigators. Endovascular therapy for ischemic stroke with perfusion-imaging selection. N Engl J Med. 2015;372:1009-18 (Citations: 1,301). Conceptualisation, design and conduct. Landmark trial showed in patients with proximal occlusion and salvageable tissue on imaging, early thrombectomy, compared with alteplase alone, improved functional outcome. Major practice changing trial ushering in the new era of endovascular stroke management.
  3. Bivard A, Levi C, Krishnamurthy V, McElduff P, Miteff F, Spratt NJ, Bateman G, Donnan G, Davis S, Parsons M. Perfusion computed tomography to assist decision making for stroke thrombolysis. Brain. 2015;138:1919-31 (Citations: 26). This study showed that perfusion CT improves the identification of patients likely to respond to thrombolysis, and also those in whom natural history may be difficult to modify with treatment.
  4. Parsons M, Spratt N, Bivard A, Campbell B, Chung K, Miteff F, O’Brien B, Bladin C, McElduff P, Allen C, Bateman G, Donnan G, Davis S, Levi C (senior author). A randomized trial of tenecteplase and alteplase for acute ischemic stroke. N Eng J Med. 2012;366:1099-107 (Citations: 227). Lead role in conceptualisation, design, funding and conduct as Co-PI, Steering Committee Chair. Reported superiority of tenecteplase over standard treatment, alteplase. NHMRC funded phase 2 trial, and subsequent funding of phase 3 trial underway. First major advance in intravenous thrombolytic since 1995. Translation at phase 3 would represent an advance of global importance.
  5. Miteff F, Levi CR, Bateman GA, Spratt N, McElduff P, Parsons MW. The independent predictive utility of CT angiographic collateral status in acute ischaemic stroke. Brain. 2009;132:2231-2238 (Citations: 213). This landmark study presented the first comprehensive analysis of the importance of collaterals in extending the ‘life expectancy’ of the ischaemic penumbra.
Prof Mark Lawler

Chair in Translational Cancer Genomics and Dean of Education in the Faculty of Medicine, Health and Life Sciences, Queen’s University Belfast

Mark has published over 180 papers in international peer review journals, including key papers in the highest impact journals (New Engl J Medicine, Lancet, Nature Medicine, Lancet Oncology, Cancer DiscoveryNature Comms, Gut etc). He has been successful in attracting over £20M of research funding. He is a member of the Board of the European Alliance for Personalised Medicine (EAPM) and developed EAPM’s research strategy. Mark’s work has been recognised by a number of national/international awards including the Vander Molen Prize for Leukaemia Research, the Ely Lilly Prize, the St Lukes Medal for Cancer Research and the Graves Medal for Medical Research.

Mark is Associate Director of Health Data Research Wales-Northern Ireland, one of only 6 substantive sites of Health Data Research UK(HDR-UK), which aims to drive innovative precision medicine and public health approaches through the use of Big Data. He is also national lead for the Cancer Data Research Strategy for HDR-UK. In the wake of the Cambridge Analytica/Facebook scandal, he recently led a pan European group in the publication of a roadmap to restore public trust in health data, published in Lancet Oncology, the premier cancer journal in the world. Mark was co-chair of the Cancer Task Team of the Clinical Working Group of the Global Alliance for Genomics and Health, an international cooperative dedicated to effective and responsible sharing of genomic and clinical data. He has authored a number of key papers including a blueprint for cancer date sharing (Nature Medicine) and a road map/call to action for a Global Cancer Knowledge Network in the New England Journal of Medicine, the top medical journal in the world. He is co-lead of an ambitious proposal to develop a Global Innovation Institute which will include the  One Health Innovation Centre (OHIC), Europe’s  first Health and Agri-Food Informatics Innovation Centre.

Mark is the Queen’s Lead of the £5M Medical Research Council-Cancer Research UK funded Personalised medicine programme Stratified Medicine in Colorectal Cancer Consortium (S:CORT), a UK-wide consortium investigating novel precision medicine approaches in CRC. His international reputation in CRC was instrumental in his leading a Critical Gaps in CRC Research Initiative, recently published in the high impact factor journal Gut; this landmark publication has attracted significant global attention (his podcast had the most “hits” of any article in the journal).

Mark is frequently invited as a guest speaker to international conferences and sits on a number of high level committees at European level including EAPM, the Scientific Board of the European Cancer Patient Coalition and the European Cancer Organisation (ECCO) Oncopolicy Forum

Mark has a strong commitment to patient-centred research/care and to addressing cancer inequalities. He was the architect of the European Cancer Patient’s Bill of Rights (BoR), a catalyst for change and empowerment tool for cancer patients which he launched in the European Parliament on World Cancer Day 2014. The BoR has been adopted across Europe and  led to the 70:35 Vision, 70% survival for all cancer patients in Europe by 2035 which was recently adopted by ECCO, the largest interdisciplinary cancer organisation in Europe. The Bill of Rights recently received The 2018 European Health Award, a prestigious award for partnerships that yield real health impact in Europe and Mark received the award on behalf of this collaborative initiative during the 2018 European Health Forum Gastein, the premier European health policy Conference  . Mark’s advocacy work was instrumental in the recent decision to recommend that boys be included in the national UK HPV vaccination programme.  He is also committed to the provision of optimal pathology and laboratory medicine for citizens in resource-limited settings and was senior author of a recent paper in The Lancet as part of The Lancet Series on Pathology and Laboratory Medicine in Low- and Middle- Income Countries.